Szu Wen Tseng, M.D.
National Institute of Cancer Research
EDUCATIONPh.D., Biomedical program, Department of Pathology, School of Medicine, University of Pennsylvania, Philadelphia, USA, 1996
M.D., Chung Shan Medical and Dental College, Taiwan, 1988
PROFESSIONAL EXPERIENCES- Attending Physician, National Institute of Cancer Research, National Health Research Institute, Taiwan (2005-present)
- Postdoctoral Fellow, Division of Molecular and Genomic Medicine, National Health Research Institute, Taiwan (1997-1998)
- Chief resident and fellow, Medical oncology fellowship joint program, National Health Research Institutes and Taipei Veterans General Hospital, Taiwan (2001-2004)
- Chief resident and fellow, Division of Hematology, Veterans General Hospital-Taipei, Taiwan (2003)
- Board-certified Internal Medicine Specialist, Taiwan (2002)
- Board-certified Medical Oncology Sub-specialist, Taiwan (2003)
- Resident, Department of Medicine, Veterans General Hospital-Taipei, Taiwan (1998-2001)
RESEARCH INTERESTSDr. Tseng's research interests are listed as the following two items:
- The bioactivities of TGF-β in the cancer cells and cancer patients. TGF-β is a multifunctional cytokine capable not only of inhibiting cell growth but also inducing tumorigenesis, depending on the stage of carcinogenesis of the cells. Currently, they have focused studies on the correlation of TGF-β regulation and anticancer drug resistance in the cancer cells and advanced cancer patients.
- Analysis of novel tumor markers in cancer patients. Presently, they have found several novel proteins which may suggest poor prognosis with highly potential of tumor metastases in cancer patients. They are now analyzing several tumor associated antigen (TAA) and TAA antibodies in the sera of cancer patients and trying to find their clinical significances.
RESEARCH ACTIVITIES & ACCOMPLISHMENTSThey have found that Stat3 activities were closely related to the TGF-β-mediated cell growth regulation in drug resistant cancer cells. By using inducible Stat3 constructs, they are now looking for the mechanisms involved in the TGF-β-mediated tumorigenesis and drug resistance.
Currently, by using sandwich ELISA, they have found that serum levels of anti-ENO1 antibodies are associated with prognosis in the advanced lung cancer patients. They plan to test several novel tumor markers and define their clinical significances in the future.
- Liu JM, Wang LS, MH Huang, Hsu WH, Yen SH, Shiau CY, Li AFY, Tiu CM, Tseng SW, and Huang BS. Topoisomerase 2α plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer 2006 (in press)
- You JY, Lee MY, Lin PC, Poh SB, Bai LY, Tseng SW, Chen CC, and Gau JP. Differential Diagnosis for primary and secondary adenocarcinoma of lung in a patient with previous history of recto-sigmoid cancer. J. Chinese Oncol. Soc. 18:23-28, 2002.
- Phinney DG, Tseng SW, Hall B, and Ryder K. Chromosomal integration dependent induction of junB by growth factors requires multiple flanking evolutionarily conserved sequences. Oncogene 13:1875-83, 1996.
- Phinney DG, Tseng SW, and Ryder K. Complex Genetic Organization of junB: Multiple blocks of flanking evolutionarily conserved sequence at the murine and human junB loci. Genomics 28:228-234, 1995. (1st and 2nd authors contributed equally to this work was noted)